{"id":841584,"date":"2026-10-14T16:49:02","date_gmt":"2026-10-14T16:49:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=841584"},"modified":"2026-10-14T16:49:02","modified_gmt":"2026-10-14T16:49:02","slug":"acromegaly-market-is-projected-to-grow-by-2036-owing-to-the-launch-of-novel-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acromegaly-market-is-projected-to-grow-by-2036-owing-to-the-launch-of-novel-therapies-delveinsight_841584.html","title":{"rendered":"Acromegaly Market is Projected to Grow by 2036 Owing to the Launch of Novel Therapies | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1791952687.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Acromegaly Market is Projected to Grow by 2036 Owing to the Launch of Novel Therapies | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1791952687.jpg\" alt=\"Acromegaly Market is Projected to Grow by 2036 Owing to the Launch of Novel Therapies | DelveInsight\" width=\"225\" height=\"118\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The market dynamics for acromegaly are witnessing steady growth driven by the Rising Disease Recognition and Diagnosis Rates, Advancements in Targeted Medical Therapies, and Increasing Demand for Convenient and Long-Acting Treatment Options. Additionally, the development of emerging therapies such as Paltusotine (Crinetics Pharmaceuticals), CAM2029 (Camurus), Debio 4126 (Debiopharm International SA), ALXN2420, MAR002 (Marea Therapeutics), and others will further influence the market.<\/div>\n<p style=\"text-align: justify;\">(Albany, New York) &ndash; October 14, 2026 &ndash; The market dynamics for acromegaly are witnessing steady growth driven by the Rising Disease Recognition and Diagnosis Rates, Advancements in Targeted Medical Therapies, and Increasing Demand for Convenient and Long-Acting Treatment Options. Additionally, the development of emerging therapies such as <strong>Paltusotine (Crinetics Pharmaceuticals), CAM2029 (Camurus), Debio 4126 (Debiopharm International SA), ALXN2420 (AstraZeneca), MAR002 (Marea Therapeutics),<\/strong> and others will further influence the market.<\/p>\n<p style=\"text-align: justify;\">DelveInsight, a leading market research firm, announces the release of its latest report, &ldquo;DelveInsight&rsquo;s Acromegaly Market Insights, Epidemiology, and Market Forecast 2036.&rdquo; This comprehensive report provides an in-depth understanding of acromegaly, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Acromegaly Market<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The market size for acromegaly across the leading markets was approximately <strong>USD 1,300 million in 2025 and is projected to grow at a CAGR of approximately 1.5% during 2026&ndash;2036.<\/strong><\/p>\n<\/li>\n<li>\n<p>The United States accounted for the largest acromegaly treatment market share in the 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.<\/p>\n<\/li>\n<li>\n<p>DelveInsight&#8217;s analysis indicates that approximately <strong>59,000<\/strong> diagnosed prevalent cases of acromegaly were reported across the 7MM in 2025.<\/p>\n<\/li>\n<li>\n<p>In the United States, the total diagnosed prevalent cases of acromegaly were estimated at approximately <strong>27,500<\/strong> in 2025, with the patient population expected to increase by 2036.<\/p>\n<\/li>\n<li>\n<p>Approximately 95% of acromegaly cases are associated with pituitary adenomas, while around 5% arise from ectopic or non-pituitary sources.<\/p>\n<\/li>\n<li>\n<p>Acromegaly is commonly diagnosed in middle-aged adults, particularly those in their 40s and 50s, due to the gradual progression of symptoms and delays in diagnosis.<\/p>\n<\/li>\n<li>\n<p>Among the EU4 countries and the UK, Germany had the highest number of diagnosed prevalent cases, while Spain had the lowest in 2025.<\/p>\n<\/li>\n<li>\n<p>Leading acromegaly companies, such as Crinetics Pharmaceuticals, Camurus, Debiopharm International SA, AstraZeneca, Marea Therapeutics, Chiesi, and others, are developing novel treatments that may influence the acromegaly market in the coming years.<\/p>\n<\/li>\n<li>\n<p>The promising acromegaly therapies in development include<strong> Paltusotine (PALSONIFY), CAM2029 (OCZYESA\/Oclaiz), Debio 4126, ALXN2420, MAR002, and others.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Keen to know more about the market? Request our sample page at<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acromegaly-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\">https:\/\/www.delveinsight.com\/sample-request\/acromegaly-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Factors Driving the Acromegaly Market<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Rising Disease Recognition and Diagnosis Rates:<\/strong> Increasing clinical awareness, improved diagnostic approaches, and the widespread use of magnetic resonance imaging (MRI) are helping identify previously undiagnosed cases of acromegaly. Since the condition often develops gradually, patients may experience symptoms for years before receiving a diagnosis. Improved screening and biochemical testing can support earlier detection and timely treatment.<\/p>\n<p style=\"text-align: justify;\"><strong>Advancements in Targeted Medical Therapies<\/strong>: The pharmacological treatment of acromegaly includes somatostatin receptor ligands (SRLs), growth hormone receptor antagonists, and dopamine agonists. These therapies help control growth hormone (GH) secretion and insulin-like growth factor 1 (IGF-1) levels in patients who are not cured by surgery or are unsuitable for surgical treatment. The development of oral medications and long-acting formulations is also improving treatment convenience and expanding therapeutic options.<\/p>\n<p style=\"text-align: justify;\"><strong>Growing Preference for Convenient and Long-Acting Treatment Options:<\/strong> Traditional injectable therapies may require repeated administration and long-term monitoring, creating treatment burdens for some patients. Emerging oral therapies such as Paltusotine and long-acting formulations such as CAM2029 are designed to provide alternative administration options. These innovations may improve treatment adherence and patient convenience while supporting the broader evolution of acromegaly management.<\/p>\n<p style=\"text-align: justify;\"><strong>Acromegaly Competitive Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\">Several acromegaly drugs in development include <strong>Paltusotine (Crinetics Pharmaceuticals), CAM2029 (Camurus), Debio 4126 (Debiopharm International SA), ALXN2420 (AstraZeneca), and MAR002 (Marea Therapeutics).<\/strong><\/p>\n<p style=\"text-align: justify;\">These candidates target different mechanisms involved in growth hormone regulation and IGF-1 control. Paltusotine is an oral nonpeptide somatostatin receptor type 2 agonist, while CAM2029 is a long-acting octreotide formulation designed for subcutaneous administration. Debio 4126 is a long-acting octreotide formulation intended for administration every three months. ALXN2420 is an investigational growth hormone receptor antagonist, while MAR002 is an investigational growth hormone receptor antagonist being developed for acromegaly. These approaches aim to improve biochemical disease control, treatment convenience, and long-term patient outcomes.<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to influence major acromegaly market share @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acromegaly-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\"> Acromegaly Treatment Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Recent Developments in the Acromegaly Market<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>In July 2026, Camurus announced that the US FDA had accepted the resubmission of the New Drug Application (NDA) for CAM2029 (Oclaiz), an extended-release octreotide injection for acromegaly. The FDA assigned a PDUFA target action date of December 18, 2026, following a Complete Response Letter issued in June 2026 concerning observations from a third-party manufacturing facility.<\/p>\n<\/li>\n<li>\n<p>In April 2026, Crinetics Pharmaceuticals announced that the European Commission had approved PALSONIFY (paltusotine) for the treatment of adults with acromegaly. It became the first once-daily oral therapy approved for this indication in the European Union.<\/p>\n<\/li>\n<li>\n<p>In January 2026, Marea Therapeutics announced positive topline results from the Phase I clinical study of MAR002 in acromegaly, supporting continued investigation of the candidate.<\/p>\n<\/li>\n<li>\n<p>In December 2025, Debiopharm announced that the first patient had been randomized in the Phase III OXTEND-03 clinical trial evaluating Debio 4126 in adults with acromegaly who were receiving somatostatin analogues.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>What is Acromegaly?<\/strong><\/p>\n<p style=\"text-align: justify;\">Acromegaly is a rare hormonal disorder characterized by excessive production of growth hormone (GH), most commonly caused by a benign tumor known as a pituitary adenoma. Excess GH stimulates the production of insulin-like growth factor 1 (IGF-1), resulting in gradual enlargement of the hands, feet, facial features, and other body tissues. The condition can also cause metabolic abnormalities and complications affecting multiple organ systems.<\/p>\n<p style=\"text-align: justify;\">Common symptoms include enlarged hands and feet, changes in facial appearance, headaches, excessive sweating, joint pain, fatigue, and changes in vision when a tumor compresses nearby structures. Patients may also develop hypertension, diabetes, sleep apnea, and cardiovascular complications.<\/p>\n<p style=\"text-align: justify;\">Diagnosis typically involves measuring serum IGF-1 levels, evaluating growth hormone suppression following an oral glucose tolerance test when indicated, and performing pituitary MRI to identify and characterize a pituitary adenoma. Early diagnosis and appropriate treatment are important to reduce complications and improve long-term outcomes.<\/p>\n<p style=\"text-align: justify;\"><strong>Acromegaly Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\">The Acromegaly epidemiology section provides insights into the historical and current acromegaly patient pool and forecasted trends for the leading markets. The acromegaly market report provides epidemiological analysis for the study period 2022&ndash;2036 across the leading markets, segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total Diagnosed Prevalent Cases of Acromegaly<\/p>\n<\/li>\n<li>\n<p>Tumor Origin-specific Diagnosed Prevalent Cases of Acromegaly<\/p>\n<\/li>\n<li>\n<p>Gender-specific Diagnosed Prevalent Cases of Acromegaly<\/p>\n<\/li>\n<li>\n<p>Tumor Size-specific Diagnosed Prevalent Cases of Acromegaly<\/p>\n<\/li>\n<li>\n<p>Total Treated Cases of Acromegaly<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Scope of the Acromegaly Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Therapeutic Assessment:<\/strong> Acromegaly current marketed and emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Acromegaly Market Dynamics:<\/strong> Key market forecast assumptions, emerging acromegaly drugs, and market outlook<\/p>\n<\/li>\n<li>\n<p><strong>Key Companies:<\/strong> <strong>Crinetics Pharmaceuticals, Camurus, Debiopharm International SA, AstraZeneca, Marea Therapeutics, Chiesi, and others<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Key Therapies: Paltusotine (PALSONIFY), CAM2029 (OCZYESA\/Oclaiz), Octreotide (MYCAPSSA), Debio 4126, ALXN2420, MAR002, and others<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, market entry strategies, and competitive landscape assessment<\/p>\n<\/li>\n<li>\n<p>Unmet Needs, KOLs&rsquo; Views, Analyst Insights, Acromegaly Market Access, and Reimbursement<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>To know more about acromegaly companies working in the treatment market, visit @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acromegaly-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kspr\"> Acromegaly Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li>\n<p>Acromegaly Market Report Introduction<\/p>\n<\/li>\n<li>\n<p>Executive Summary for Acromegaly<\/p>\n<\/li>\n<li>\n<p>SWOT Analysis of Acromegaly<\/p>\n<\/li>\n<li>\n<p>Acromegaly Patient Share (%) Overview at a Glance<\/p>\n<\/li>\n<li>\n<p>Acromegaly Market Overview at a Glance<\/p>\n<\/li>\n<li>\n<p>Acromegaly Background and Overview<\/p>\n<\/li>\n<li>\n<p>Acromegaly Epidemiology and Patient Population<\/p>\n<\/li>\n<li>\n<p>Country-Specific Patient Population of Acromegaly<\/p>\n<\/li>\n<li>\n<p>Acromegaly Current Treatment and Medical Practices<\/p>\n<\/li>\n<li>\n<p>Acromegaly Unmet Needs<\/p>\n<\/li>\n<li>\n<p>Acromegaly Emerging Therapies<\/p>\n<\/li>\n<li>\n<p>Acromegaly Market Outlook<\/p>\n<\/li>\n<li>\n<p>Country-Wise Acromegaly Market Analysis (2022&ndash;2036)<\/p>\n<\/li>\n<li>\n<p>Acromegaly Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li>\n<p>Acromegaly Market Drivers<\/p>\n<\/li>\n<li>\n<p>Acromegaly Market Barriers<\/p>\n<\/li>\n<li>\n<p>Acromegaly Appendix<\/p>\n<\/li>\n<li>\n<p>Acromegaly Report Methodology<\/p>\n<\/li>\n<li>\n<p>DelveInsight Capabilities<\/p>\n<\/li>\n<li>\n<p>Disclaimer<\/p>\n<\/li>\n<li>\n<p>About DelveInsight<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kirti Sharma<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=acromegaly-market-is-projected-to-grow-by-2036-owing-to-the-launch-of-novel-therapies-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=acromegaly-market-is-projected-to-grow-by-2036-owing-to-the-launch-of-novel-therapies-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The market dynamics for acromegaly are witnessing steady growth driven by the Rising Disease Recognition and Diagnosis Rates, Advancements in Targeted Medical Therapies, and Increasing Demand for Convenient and Long-Acting Treatment Options. Additionally, the development of emerging therapies such as &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/acromegaly-market-is-projected-to-grow-by-2036-owing-to-the-launch-of-novel-therapies-delveinsight_841584.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,420,404],"tags":[],"class_list":["post-841584","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/841584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=841584"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/841584\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=841584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=841584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=841584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}